Taiho Oncology and Cullinan Therapeutics Seek FDA Approval for Innovative Lung Cancer Drug Zipalertinib Taiho Oncology and Cullinan Therapeutics have begun filing a New Drug Application for Zipalertinib, aimed at treating advanced non-small cell lung cancer with specific mutations, targeting FDA's accelerated approval pathway.

Taiho Oncology and Cullinan Therapeutics Seek FDA Approval for Innovative Lung Cancer Drug Zipalertinib #USA #Princeton #Taiho_Oncology #Zipalertinib #EGFR_Mutations

Lung Cancer Research Foundation Unveils 2025 Team Science Award for EGFR Mutations The Lung Cancer Research Foundation announces a new funding initiative for innovative lung cancer treatments focusing on EGFR mutations, with a goal to cure.

Lung Cancer Research Foundation Unveils 2025 Team Science Award for EGFR Mutations #USA #New_York #Lung_Cancer #EGFR_Mutations #Team_Science_Award

Rybrevant® Gains Approval for NSCLC Treatment with Chemotherapy for EGFR Mutations Johnson & Johnson's Rybrevant® receives new approval for use with chemotherapy in treating EGFR mutation-positive non-small cell lung cancer after TKI failure.

Rybrevant® Gains Approval for NSCLC Treatment with Chemotherapy for EGFR Mutations #Japan #Tokyo #RYBREVANT #Non-Small_Cell_Lung_Cancer #EGFR_Mutations